MedTrace Logo

Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial

NCT00329992 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-01-20

No results posted yet for this study

Summary

Participants are randomly assigned to either 16 sessions of Brief Eclectic Psychotherapy (Gersons et al. (2000) Journal Trauma Stress 13: 333-348), comprising psychoeducation, exposure, mementos and writing assignments, domain of meaning and integration, farewell ritual, or a minimal attention control group that will be offered 16 sessions of BEP after a waiting time of four months. Participants in the minimal attention control group receive monthly telephone calls and complete a symptom self monitoring diary (Tarrier, N. et al. (1999) Behavior Therapy 30: 597-605) for three weeks.

Conditions

  • Chronic Posttraumatic Stress Disorder

Interventions

BEHAVIORAL

Brief Eclectic Psychotherapy for PTSD

16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Herrmann-Klaus-Stiftung, Switzerland

    collaborator UNKNOWN

  • Olga Mayenfisch Stiftung, Zurich, Switzerland

    collaborator UNKNOWN

  • Jubiläumsspende für die Universität Zürich, Switzerland

    collaborator UNKNOWN

  • University of Zurich

    lead OTHER

Principal Investigators

  • Ulrich Schnyder, MD · University of Zurich

  • Lutz Wittmann, MA · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-05-31
Completion
2009-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329992 on ClinicalTrials.gov